Table 2.

P values for enrichment of correlation of gene groups with cardiac parameters for basal, isoproterenol, and change with isoproterenol state

	BASAL				ISO				ISO - BASAL
Phenotype	Cardiac TF	Chr	Fetal	Hyp	Cardiac TF	Chr	Fetal	Hyp	Cardiac TF	Chr	Fetal	Hyp
Total heart	0.51	0.41	0.44	0.31	0.47	0.32	0.0058	0.40	0.36	0.58	0.039	0.36
Left ventricle	0.41	0.33	0.43	0.27	0.54	0.27	0.028	0.31	0.32	0.52	3.53E-04	0.28
Right ventricle	0.53	0.09	0.28	0.020	0.60	0.06	0.017	0.16	0.48	0.43	0.32	0.06
Left atrium	0.50	0.12	0.51	0.62	0.43	0.64	6.93E-04	0.32	0.19	0.65	0.042	0.07
Right atrium	0.63	0.57	0.036	0.64	0.36	0.60	0.20	0.17	0.29	0.28	0.14	0.21
Lung	0.0069	0.46	0.63	0.28	0.66	0.45	0.0061	0.52	0.05	0.64	0.27	0.14
Liver	0.43	0.64	0.44	0.32	0.54	0.57	0.09	0.07	0.19	0.49	0.31	0.31
Adrel	0.38	0.60	0.63	0.35	0.43	0.26	0.57	0.51	0.59	0.51	0.59	0.64
Normalized TH	0.36	0.22	0.38	0.19	0.46	0.27	0.09	0.66	0.43	0.32	0.0048	0.50
Normalized LV	0.14	0.26	0.37	0.33	0.55	0.19	0.26	0.59	0.34	0.31	4.59E-04	0.44
Normalized RV	0.63	0.021	0.15	0.031	0.54	0.042	0.24	0.12	0.52	0.52	0.53	0.32
Normalized LA	0.53	0.59	0.63	0.61	0.50	0.55	0.0018	0.56	0.24	0.65	0.07	0.16
Normalized RA	0.11	0.57	0.41	0.20	0.36	0.60	0.21	0.45	0.35	0.19	0.19	0.22
Normalized Lung	0.65	0.61	0.61	0.63	0.13	0.61	0.050	0.37	0.0044	0.65	0.27	0.13
Normalized liver	0.24	0.46	0.54	0.21	0.18	0.49	0.27	0.11	0.14	0.54	0.07	0.35
Normalized Adrel	0.48	0.63	0.48	0.63	0.32	0.13	0.66	0.57	0.47	0.65	0.61	0.65
Fibrosis (score)	0.55	0.61	0.55	0.39	0.61	0.61	0.0093	0.52	0.46	0.64	0.023	0.60
TG	0.37	0.41	0.61	0.53	0.61	0.63	0.28	0.66	0.66	0.60	0.26	0.62
Cholesterol	0.61	0.63	0.19	0.19	0.63	0.43	0.043	0.43	0.63	0.36	0.59	0.60
HDL	0.61	0.50	0.10	0.14	0.63	0.27	0.21	0.39	0.58	0.20	0.51	0.52
UC	0.55	0.52	2.04E-04	0.41	0.59	0.62	0.13	0.46	0.60	0.50	0.53	0.61
FFA	0.27	0.12	0.59	0.22	0.64	0.36	0.06	0.63	0.22	0.046	0.30	0.0042
Glucose	0.64	0.49	0.11	0.66	0.38	0.56	0.51	0.020	0.44	0.36	0.45	0.57
Fibrosis (area)	0.21	0.61	0.06	0.35	0.59	0.52	0.06	0.36	0.52	0.40	0.050	0.31
Heart rate	0.27	0.63	0.18	0.49	0.54	0.64	0.31	0.43	0.37	0.22	0.24	0.20
IVSd	0.40	0.33	0.06	0.47	0.31	0.07	0.52	0.53	0.10	0.48	0.57	0.36
LVIDd	0.39	0.56	0.10	0.24	0.62	0.60	0.0022	0.36	0.55	0.66	0.09	0.55
PWd	0.66	0.13	0.06	0.29	0.54	0.21	0.44	0.0045	0.54	0.58	0.30	0.024
IVSs	0.61	0.0033	0.050	0.13	0.31	0.0045	0.56	0.030	0.52	0.62	0.52	0.39
LVIDs	0.36	0.61	0.16	0.31	0.56	0.34	0.016	0.26	0.62	0.36	0.20	0.32
PWs	0.65	0.60	0.40	0.62	0.58	0.0068	0.59	0.0026	0.18	0.20	0.41	0.0018
ET	0.65	0.29	0.52	0.61	0.55	0.67	0.17	0.32	0.35	0.30	0.49	0.35
E	0.63	0.29	0.59	0.52	0.39	0.65	0.20	0.31	0.27	0.12	0.27	0.27
A	0.59	0.040	0.05	0.13	0.45	0.022	0.53	0.11	0.15	0.46	0.45	0.62
E/A	0.39	0.0040	0.28	0.20	0.41	0.05	0.56	0.28	0.21	0.21	0.57	0.64
A/E	0.46	0.0014	0.28	0.10	0.61	0.27	0.56	0.56	0.13	0.64	0.22	0.44
FS	0.43	0.50	0.21	0.36	0.41	0.032	0.26	0.30	0.48	0.43	0.19	0.38
IVS/PWd	0.60	0.44	0.60	0.56	0.31	0.66	0.58	0.62	0.34	0.61	0.51	0.35
IVS/PWs	0.26	0.0017	0.15	0.0053	0.31	0.61	0.31	0.54	0.36	0.53	0.61	0.20
RWTd	0.24	0.32	0.19	0.16	0.42	0.19	0.43	0.12	0.64	0.65	0.44	0.23
PWTH	0.59	0.15	0.13	0.15	0.64	0.63	0.31	0.63	0.06	0.31	0.47	0.36
Vold	0.32	0.61	0.12	0.43	0.61	0.62	0.010	0.56	0.56	0.67	0.09	0.35
Vols	0.27	0.57	0.17	0.32	0.36	0.31	0.012	0.48	0.61	0.63	0.48	0.30
EF	0.52	0.60	0.11	0.36	0.39	0.07	0.11	0.35	0.50	0.37	0.21	0.33
LVM	0.57	0.39	0.19	0.26	0.65	0.32	0.0015	0.16	0.43	0.046	0.06	0.54
LVMc	0.57	0.39	0.19	0.26	0.65	0.32	0.0015	0.16	0.43	0.047	0.06	0.54
Vcf	0.23	0.60	0.35	0.22	0.32	0.0069	0.58	0.11	0.61	0.53	0.32	0.31
MNSER	0.31	0.51	0.46	0.21	0.36	0.027	0.60	0.24	0.62	0.60	0.34	0.43
Upreg genes	0.47	0.30	0.31	0.16	0.19	0.31	0.66	0.41	0.19	0.16	0.27	0.010
Downreg genes	0.61	0.21	0.29	0.12	0.20	0.012	0.46	5.30E-06	0.033	0.028	0.43	0.15

Subset of probes representing cardiac transcription factors (TF), chromatin regulators, fetal gene program, and hypertrophic regulators were analyzed by Pearson correlation to determine significance with association to phenotype. Here, enrichment of these gene groups was compared with respect to all probes that had detectable expression on the microarray. Measured phenotypes include: mass of heart and indicated chambers and other tissues (these were, in addition, normalized to body weight); fibrosis, measured independently by visual scoring and area quantification; plasma triglycerides (TG), cholesterol, HDL cholesterol, unesterified cholesterol (UC), glucose, free fatty acids (FFA); echocardiogram parameters including heart rate, diastolic and systolic interventricular septal thickness (IVSd, IVSs), left ventricular internal diameter (LVIDd, LVIDs), posterior wall thickness (PWd, PWs), ejection time (ET), early and late ventricular filling velocities (E, A) and their ratios, fractional shortening (FS), diastolic relative wall thickness (RWTd), posterior wall thickening (PWTH), end diastolic and systolic end volume (Vold, Vols), ejection fraction (EF), left ventricular mass (LVM) and LVW corrected for growth (LVMc), mean velocity of circumferential fiber shortening (Vcf), and mean normalized systolic ejection rate (MNSER). Additionally, the numbers of up- and downregulated genes after isoproterenol treatment for each strain (Upreg and Downreg) were measured to determine whether overall changes in transcription are correlated to gene groups. Significant enrichment is indicated in boldface.